Archives

Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology

M Ventures

Merck KGaA, Darmstadt, Germany and Artios will conduct collaborative research and Merck KGaA, Darmstadt, Germany shall have the right to opt into exclusive development and commercialization of compounds on up to 8 targets

Artios to receive US$30 million in up-front and near-term payments, plus double-digit option fees and up to US$860 million total milestones per target

Collaboration to leverage significant expertise and R&D resources of Merck KGaA, Darmstadt, Germany in the field of DNA Damage Response to identify and develop precision oncology medicines targeting nucleases

Darmstadt, Germany, Cambridge, UK and New York, USA, 3rd December 2020: Merck KGaA, Darmstadt, Germany, a leading science and technology company and Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, today announced a global three year strategic research collaboration to discover and develop multiple precision oncology drugs.

“Our platform has the potential to revolutionize targeted treatment in cancer and deliver on the promise of precision medicine. This collaboration will leverage the potential of our unique discovery platform of novel DNA repair nuclease inhibitors and targets that we have been developing. The partnership puts us in an exceptional position to focus internal efforts on our leading portfolio of assets which includes a small-molecule ATR inhibitor and a Polθ programme, both in candidate IND evaluation,” said Niall Martin, Chief Executive Officer at Artios Pharma.

“Targeting DNA damage response has the potential to provide an important therapeutic option for many patients in need of new treatments. We are excited about working with Artios to develop novel precision oncology medicines as we move towards changing the current paradigm in cancer treatment. This collaboration further strengthens our leadership and expertise in the field and discovery of DDR inhibitors and complements our multiple innovative assets currently being evaluated in several Phase I and Phase II clinical studies,” said Andree Blaukat, SVP and Head Translational Innovation Platform Oncology & Immuno-Oncology, at Merck KGaA, Darmstadt, Germany.

Under the terms of the agreement, the companies will leverage Artios’s proprietary nuclease targeting discovery platform to jointly identify multiple synthetic lethal targets for precision oncology drug candidates. During this joint research collaboration, Merck KGaA, Darmstadt, Germany will contribute its significant expertise and resources in the field of DDR and will have exclusive worldwide rights to develop and commercialize selected therapeutics discovered under the collaboration. The collaboration does not include Artios’s lead programmes, Polθ and ATR inhibitors, for which Artios will retain all rights.

Nucleases are critical enzymes involved in the maintenance of genomic integrity. Cancer cells are dependent on nucleases for their survival in response to DNA damage. Also, in certain cancers which exhibit mutations in DNA damage response pathways, inhibiting key nucleases can lead to selective cancer cell killing i.e. synthetic lethality.

As part of the agreement, Artios will receive a payment of US$30 million in the form of an up-front and near-term payments. If Merck KGaA, Darmstadt, Germany chooses to exercise the option, subject to double-digit option fees, Artios will be eligible to receive up to US$860 million per target, in addition to up to double digit royalty payments on net sales of each product commercialized by Merck KGaA, Darmstadt, Germany.

Subject to certain conditions, Artios has opt-in rights for joint development and commercialization with Merck KGaA, Darmstadt, Germany for the programmes.

For more information, please contact:

Artios Pharma Ltd.
Niall Martin, Chief Executive Officer
+44 01223 867 867

Media & IR Enquiries
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Manel Mateus
artios@optimumcomms.com
+44 020 3922 1906

Merck KGaA, Darmstadt, Germany
Gangolf Schrimpf, Media Relations
gangolf.schrimpf@merckgroup.com
+49 6151 72-9591

** Notes to Editors

About Artios Pharma Ltd.**

Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The Company, founded by SV Health Investors in 2016, is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. It has a unique partnership with Cancer Research UK (CRUK), and collaborations with leading DNA repair researchers worldwide, such as The Institute of Cancer Research (ICR), London, the Netherlands Cancer Institute (NKI) and the National Centre for Biomolecular Research at Masaryk University in the Czech Republic, with their expertise in DNA repair nucleases. Artios is building a pipeline of next-generation DDR programmes to target hard to treat cancers. It is backed by blue chip investors including: AbbVie Ventures, Andera Partners (formerly EdRIP), Arix Bioscience plc, IP Group plc, LSP, M Ventures, Novartis Venture Fund (NVF), Pfizer Ventures and SV Health Investors. Artios is based at the Babraham Research Campus in Cambridge, UK, with offices in New York City, USA.www.artiospharma.com

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany generated sales of € 16.2 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck KGaA, Darmstadt, Germany’s technological and scientific advances. This is how Merck KGaA, Darmstadt, Germany has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck KGaA, Darmstadt, Germany holds the global rights to the Merck KGaA, Darmstadt, Germany name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.

Categories: News

Tags:

Funds advised by Apax sell Unilabs to A.P. Moller Holding

Apax

Funds advised by Apax Partners LLP (the “Apax Funds”) announced today that they have agreed to sell their controlling stake in Unilabs (the “Company”), a leading pan-European provider of laboratory and imaging diagnostics services, to A.P. Moller Holding, the parent company of the Danish A.P. Moller Group founded and run by the Maersk family. Financial details of the transaction were not disclosed.

Drawing on Apax’s deep knowledge of the healthcare sector, the Apax team identified Unilabs as an attractive company operating in a highly fragmented market with significant expertise in best practice lab and imaging operations. The Apax Funds first invested in a minority stake in Unilabs in 2007, taking the Company private from the Swiss Stock Exchange and subsequently merging it with Capio Diagnostics, a Nordic laboratory and imaging business.

In 2017, the Apax Funds gained majority control of the Company, acquiring the outstanding shareholding in Unilabs. The Apax Funds subsequently proceeded to invest in people, technology, and M&A and, under the Apax Funds’ ownership, Unilabs accelerated its organic growth to become a European leader in digital imaging and digital pathology diagnostics. During this period, Unilabs also completed over 50 add-on acquisitions, helping enhance the Company’s product offering and expand its geographical footprint.

Today Unilabs is the only European player covering the full spectrum of diagnostics across laboratory, imaging and pathology services at scale. Headquartered in Switzerland, Unilabs now employs over 12,000 people across 15 countries.

Steven Dyson, Partner at Apax, said: “Unilabs is an excellent example of the Apax Funds’ transformative ownership approach, focusing on healthcare fundamentals and partnering with exceptional management teams. It has been great to work with Jos, Michiel and the whole Unilabs team over the past few years. The Company has undergone significant transformation which includes accelerating organic growth, expanding into new markets through strategic acquisitions and leading the digitalisation of healthcare, to become a leading provider of diagnostics services in Europe.”

Arthur Brothag, Partner at Apax, added: “We are proud to have helped Unilabs build and scale the business and we would like to thank Jos, Michiel, and the team and wish them every success for the future in this new exciting chapter with their new partner.”

Michiel Boehmer, Chief Executive Officer of Unilabs, said “Unilabs has truly scaled its operations in the last few years and Apax has been an outstanding partner for me and the management team. Their combined experience in healthcare and technology has not only helped us enhance our existing offering and geographic reach, but also allowed us to become a pioneer in digital diagnostics and in the adoption of artificial intelligence in telemedicine. As we embark on our next chapter, I want to thank both the Apax and the Unilabs team for all their hard work and dedication over the last few years.”

Jos Lamers, Chairman of Unilabs, added: “I would like to thank Apax, who have been part of Unilabs’ journey since 2007. Apax supported our strategy, helped us grow into the international diagnostics champion we are today, and set us up perfectly for the next chapter. Also, I’d like to share my appreciation and admiration to all the Unilabs colleagues, for their tireless efforts to support our customers and patients every day.”

The Apax Funds have a strong track record of investing in the Healthcare sector, having completed more than 80 investments over the last 30 years across multiple geographies, including the US, Europe and Asia. Current and recent investments include Eating Recovery Center, a US provider of eating disorder and mood and anxiety treatments, Rodenstock, a European provider of premium, highly individualised ophthalmic lenses, InnovAge, a US provider of senior care services, the medical device companies Candela and Vyaire, as well as the specialty pharma company Neuraxpharm.

Apax was advised by Rothschild&Co (M&A adviser), and Linklaters (legal advisers). The transaction is expected to close in the next few months, subject to customary closing conditions and regulatory approvals.

Categories: News

Tags:

IK Partners acquires DA Languages from Foresight

IK Partners

IK Partners (“IK”) is pleased to announce that the IK Small Cap III Fund has acquired DA Languages Ltd. (“DAL” or “the Company”) from Foresight Group (“Foresight”). Financial terms of the transaction are not disclosed.

Founded in 1998 and headquartered in Manchester, DAL is one of the fastest growing language services providers in the UK, providing critical services to organisations communicating with non-English speakers. With a network of over 8000 mother tongue interpreters and translators, DAL’s offering spans face-to-face, video and telephone interpretation along with written translation services. Over 450 languages and dialects are provided, including sign language, enabling better outcomes for all stakeholders. Promoting inclusivity and equality is at the heart of DAL’s operations, ensuring that language barriers are removed in critical situations, particularly in healthcare and legal settings.

IK is acquiring the Company from Foresight, a leading listed infrastructure and private equity investment manager, which invested into DAL from its Regional Investment Fund in May 2018. During Foresight’s ownership, DAL has strengthened its management team, substantially grown its employee base and developed a highly diverse client base of NHS trusts, charities, city councils, and corporates, building a strong reputation for quality provision. The business has also invested significantly in technology and IT infrastructure to support its clients, including the acquisition of Miton Systems, an interpreting technology specialist, enabling DAL to offer its own proprietary video and telephone remote interpreting products.

The incumbent management team, led by Managing Director Matthew Taylor, as well as the founder, Actar Arya, will be reinvesting in the business. IK will work alongside the team to continue scaling DAL both organically and through add-on acquisitions, with a particular focus on investing further in DAL’s differentiated technology offering to broaden the client base across the public and private sectors and expand its range of services.

Tom Salmon, Partner at IK Partners and Advisor to the Small Cap III Fund, commented: “DAL is an excellent business operating in a market underpinned by attractive, long-term growth prospects. We have been very impressed with the achievements of Matthew and the rest of the team in broadening the business’ framework coverage and client base and further developing DAL’s proprietary technology offering. With our strong track record in supporting European technology-enabled services businesses to scale rapidly, we are delighted to be partnering with the management team on the next phase of the business’ journey.”

Matthew Taylor, Managing Director of DA Languages, commented: “We would like to thank the team at Foresight for their support over the past three and a half years; during which time we have grown our offering considerably to meet the critical needs of a broader range of customers. We are excited to partner with IK and benefit from their expertise and experience to further enhance our quality service and technology proposition.”

Claire Alvarez, Partner at Foresight, commented: “It has been such a positive experience working with Matt, Actar and the wider team at DAL, helping them expand their services to support vulnerable people. We are delighted that we have been able to support the Company’s rapid growth, creating so many new jobs whilst making such a worthwhile impact. We wish the team every success for the future.”

For further questions, please contact:
IK Partners
Vidya Verlkumar
Phone: +44 (0) 7787 558 193
vidya.verlkumar@ikpartners.com

Foresight Group
Influential
Chris Barry
Phone: +44 (0)7733 103 693
barry@thisisinfluential.com

About IK Partners

IK Partners (“IK”) is a European private equity firm focused on investments in the Benelux, DACH, France, Nordics and the UK. Since 1989, IK has raised more than €14 billion of capital and invested in over 155 European companies. IK supports companies with strong underlying potential, partnering with management teams and investors to create robust, well-positioned businesses with excellent long-term prospects. For more information, visit www.ikpartners.com

Read More

About DA Languages

D.A Languages Ltd. is a Manchester based language services provider delivering face-to-face, video and telephone interpreting, and written translation services to corporate clients, charities, NHS trusts and city councils. Founded in 1998, D.A. Languages has established an extensive database of 8,000 Mother Tongue Interpreters and Translators offering over 450 languages, making it one of the major language services providers in the UK. For more information, visit www.dalanguages.co.uk

Read More

About Foresight Group

Foresight Group was founded in 1984 and is a leading listed infrastructure and private equity investment manager. With a long-established focus on ESG and sustainability-led strategies, it aims to provide attractive returns to its institutional and private investors from hard-to-access private markets. Foresight manages over 300 infrastructure assets with a focus on solar and onshore wind assets, bioenergy and waste, as well as renewable energy enabling projects, energy efficiency management solutions, social and core infrastructure projects and sustainable forestry assets. Its private equity team manages eight regionally focused investment funds across the UK, supporting over 120 SMEs. Its Foresight Capital Management team manages four funds investing in listed real assets with environmental and social benefits, exceeding £1.3 billion Assets Under Management (AUM). Foresight operates from 12 offices across six countries in Europe and Australia with AUM of £8.1 billion as of 30 September 2021. Foresight Group Holdings Limited listed on the Main Market of the London Stock Exchange in February 2021. For more information, visit https://www.fsg-investors.com/

Read More

Categories: News

Tags:

Specialist for medical polymer materials DETAX resolves ownership succession in the course of a management buy-out

Ecm
  • DETAX is a leading global supplier of biocompatible silicones and light-curing 3D resins for medical applications in the dental and audio sector.
  • As an innovative specialist in polymer materials, DETAX offers its customers a high-quality and extensively MDR-certified product portfolio and positions itself as a pioneer in the dynamic environment of 3D printing materials.
  • The company considers itself as a partner to a broad and loyal customer base, thereby enjoying an excellent reputation thanks to its consistently high product and service quality.
  • The Investor Consortium of ECM, PINOVA and Gilde Healthcare Private Equity supports DETAX and the management team in settling the ownership succession through a management buy-out. Together, the partners want to build on and further expand DETAX’s successful growth track.

An Investor Consortium consisting of funds managed by ECM Equity Capital Management GmbH (“ECM”), PINOVA Capital GmbH (“PINOVA”) and Gilde Healthcare (“Gilde Healthcare Private Equity”) (together the “Investor Consortium”) has acquired a majority stake in DETAX Group, the leading supplier of polymer materials for medical applications, in the context of a management buy-out. The two long-term managing directors, Mrs. Ursula Juretzki-Mangold and Mr. Ralf König, have invested alongside the Investor Consortium as part of the transaction. After more than 65 years of ownership, the transition from the owner family Regneri to the new owners has been completed. Together with the Investor Consortium, the management team will continue the successful development and will lead DETAX into the next growth phase. The transaction is subject to merger control approvals and financial details are not disclosed.

Specialist for medical materials

DETAX, based in Ettlingen, Germany, was founded in 1953 and today employs approx. 110 people. As a specialist in polymer materials, the group offers its customers a comprehensive product portfolio of dental and otoplastic consumables. The group serves an international, broadly diversified and loyal customer base. End users of the products include dental practices, dental laboratories as well as audiologists and audio laboratories. The group operates in a non-cyclical, highly regulated market environment. Complying with such regulation, DETAX holds all relevant MDR certificates. This makes DETAX one of the first companies in the industry with an extensive MDR-certified product portfolio.

Potential for internationalization, digitization, and innovations in a growing market environment

The company’s attractive end markets are continuously growing, driven by sustainable trends such as socio demographics, digitization and increasing regulatory requirements. Particularly 3D printing materials, an area in which DETAX is a pioneer with an excellent market standing, are experiencing a dynamic development. The Investor Consortium and the management team aim to further promote growth with targeted investments in DETAX’s headquarters in Ettlingen. Due to its long-standing, strong market positioning and high innovative strength, DETAX is in an excellent position to leverage such growth. Particularly strong growth potential stems from further internationalization, new customer acquisitions as well as active market consolidation. The Investor Consortium will contribute with its extensive and complementary experience in accompanying growth and internationalization as well as executing buy-and-build strategies.

Following the transaction, Peter Regneri, long-time shareholder and managing director, emphasizes the importance of handing over DETAX to an experienced consortium of mid-market investors with an international positioning, that is equipped to secure and continue the successful development of the company.

Ursula Juretzki-Mangold and Ralf König, managing directors and future shareholders say: “We are proud of what the entire DETAX team has achieved in recent years. Together, we were able to accomplish dynamic growth, particularly through internationalization and new product innovations. With the Investor Consortium, we have found strong partners who support us with many years of experience and international know-how in the healthcare and medical technology markets. Together with our partners, we plan to invest in further product innovations and digitization as well as the further strengthening of our headquarters in Ettlingen.”

Tim Krume, Director at ECM, adds: “DETAX is an exceptionally attractive company. We are excited about the highly professional organization, led by a high-calibre, experienced and motivated management team, the strong market positioning as well as the excellent reputation of the group as a leading specialist for medical materials. We are extremely pleased to accompany DETAX’s successful growth trajectory in partnership with the management team.”

Herbert Seggewiß, Partner at PINOVA, further adds: “We are impressed by the development of the group and the entrepreneurial performance of the management team. We were particularly impressed by the high-quality and extensively MDR-certified product portfolio, the long-standing loyal partnerships with customers and suppliers, and the high level of innovation with a strong track record. We look forward to a successful collaboration with the management team.”

Robert Stein, Partner at Gilde Healthcare Private Equity, notes, “DETAX represents an excellent basis for further organic and inorganic growth. We look forward to adding value in the future with our broad international network as well as our deep industry expertise, especially with respect to buy-and-build.”

The Investor Consortium was advised on the transaction by KWM (legal and structuring), CODEX (market), PwC (finance & tax), Shearman & Sterling (financing documentation), GCA Altium (debt advisor) and Willis Towers Watson (insurance). Responsible for the transaction at ECM are Tim Krume, Axel Eichmeyer and Paul Hansen, at PINOVA Herbert Seggewiß, David Gilli and Aylin Akkay and at Gilde Healthcare Private Equity Robert Stein, Tom Klein Robbenhaar and Julian Primer. DETAX was jointly advised on the transaction by CMS, Crowe BPG and Kanzlei Wangler.

About DETAX Group

DETAX, headquartered in Ettlingen with around 110 employees, is a specialist for medical materials. For more than 65 years, DETAX has been developing silicones and light-curing resins for medical applications and 3D printing. The company is one of the world’s leading specialists in polymer materials with a focus on the dental and audio sectors.

Further information at: www.detax.de

About PINOVA Capital GmbH

PINOVA Capital is an independent private equity firm investing in high-growth technology companies in German-speaking regions. PINOVA Capital focuses on “Mittelstand” companies with sales between €10 million and €75 million in the sectors industrial technology and information technology, characterized by significant growth potential, sustainable competitive advantages and a strong market position in their niche.

Further information at: www.pinovacapital.com

About Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor with two fund strategies: Venture&Growth and Private Equity. The firm is headquartered in Utrecht (The Netherlands) with local offices in Frankfurt (Germany) and Cambridge (United States). Gilde Healthcare Private Equity participates in profitable lower mid-market healthcare companies based in North-Western Europe. The Private Equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market. Gilde Healthcare Venture & Growth invests in medtech, healthtech and therapeutics in Europe and North America.

Further information at: www.gildehealthcare.com

About ECM Equity Capital Management GmbH

ECM is a trusted growth partner for mid-sized enterprises and entrepreneurs in German-speaking Europe. Since 1995, ECM has raised the private equity funds GEP I-V with aggregate equity commitments of more than €1 billion and currently invests out of the fifth fund GEP V (€325 million). The funds invest primarily in leading mid-market companies with attractive growth potential in the context of ownership successions, partnership transactions and corporate spin-offs.

Further information at: www.ecm-pe.de

Categories: News

Tags:

PhotonFirst successfully closes 11M Series A funding

ActiveCapital

Leading integrated photonics sensing systems supplier for advanced applications in aerospace, automotive, medical, high-tech equipment, energy and infrastructure

Dutch photonics scale-up to execute roadmap to IPO in 2025

PhotonFirst International, a leading pioneer in integrated photonics sensing solutions for advanced applications, announced to have successfully closed its Series A funding. Jointly, their largest shareholder, Amsterdam based private equity firm Active Capital Company, and new investor PhotonDelta have jointly committed 11 million Euro to fund the 5-year business plan of the company. Simultaneously, Board members Ilko Bosman (CFO) and Daan Kersten (CEO) have co-invested and the entire PhotonFirst team will participate through a phantom stock program. The majority of the investment will be used for next generation technology & product development and expansion of the commercial footprint worldwide. The deeptech company plans for an IPO in 2025 as global innovation leader based on its 15-year heritage in integrated photonics.

“We are grateful and proud that both Active Capital Company and PhotonDelta have confirmed our ambitious 5-year plan and team-up with us to successfully execute on it“, Daan Kersten, CEO said. “As proven solid partners, we have the backing that will allow us to focus on accelerating our commercial efforts while continuing to build on our technology“, added Ilko Bosman, CFO of PhotonFirst.

“*We believe in the vision and strategy of PhotonFirst and see great potential in scaling the technology. The Board has demonstrated their execution power and is on track to deliver on the plan, we are confident our funding allows them to accelerate and expand.” according to Victor Schols, partner of Active Capital Company. “PhotonFirst is a global frontrunner in integrated photonics sensing solutions. This company represents perfectly what the PhotonDelta ecosystem is all about: inventing, developing and manufacturing world class products that make a difference. We are proud to invest in this team and become part of their success.” concluded Ewit Roos, CEO of PhotonDelta.

Categories: News

Gilde Healthcare Private Equity as part of Investor Consortium acquires DETAX

GIlde Healthcare
December 3, 2021
Frankfurt am Main, Munich and Ettlingen (Germany)
Specialist for medical polymer materials DETAX resolves ownership succession in the course of a management buy-out and continues its successful growth track together with a strong Investor Consortium

 ·    DETAX is a leading global supplier of biocompatible silicones and light-curing 3D resins for medical applications in the dental and audio sector.
·    As an innovative specialist in polymer materials, DETAX offers its customers a high-quality and extensively MDR-certified product portfolio and positions itself as a pioneer in the dynamic environment of 3D printing materials.
·    The company considers itself as a partner to a broad and loyal customer base, thereby enjoying an excellent reputation thanks to its consistently high product and service quality.
·    The Investor Consortium of ECM, PINOVA and Gilde Healthcare Private Equity supports DETAX and the management team in settling the ownership succession through a management buy-out. Together, the partners want to build on and further expand DETAX’s successful growth track.

An Investor Consortium consisting of funds managed by ECM Equity Capital Management GmbH (“ECM”), PINOVA Capital GmbH (“PINOVA”) and Gilde Healthcare Private Equity (“Gilde Healthcare”) (together the “Investor Consortium”) has acquired a majority stake in DETAX Group, the leading supplier of polymer materials for medical applications, in the context of a management buy-out. The two long-term managing directors, Mrs. Ursula Juretzki-Mangold and Mr. Ralf König, have invested alongside the Investor Consortium as part of the transaction. After more than 65 years of ownership, the transition from the owner family Regneri to the new owners has been completed. Together with the Investor Consortium, the management team will continue the successful development and will lead DETAX into the next growth phase. The transaction is subject to merger control approvals and financial details are not disclosed.

Specialist for medical materials
DETAX, based in Ettlingen, Germany, was founded in 1953 and today employs approx. 110 people. As a specialist in polymer materials, the group offers its customers a comprehensive product portfolio of dental and otoplastic consumables. The group serves an international, broadly diversified and loyal customer base. End users of the products include dental practices, dental laboratories as well as audiologists and audio laboratories. The group operates in a non-cyclical, highly regulated market environment. Complying with such regulation, DETAX holds all relevant MDR certificates. This makes DETAX one of the first companies in the industry with an extensive MDR-certified product portfolio.

Potential for internationalization, digitization, and innovations in a growing market environment
The company’s attractive end markets are continuously growing, driven by sustainable trends such as socio demographics, digitization and increasing regulatory requirements. Particularly 3D printing materials, an area in which DETAX is a pioneer with an excellent market standing, are experiencing a dynamic development. The Investor Consortium and the management team aim to further promote growth with targeted investments in DETAX’s headquarters in Ettlingen. Due to its long-standing, strong market positioning and high innovative strength, DETAX is in an excellent position to leverage such growth. Particularly strong growth potential stems from further internationalization, new customer acquisitions as well as active market consolidation. The Investor Consortium will contribute with its extensive and complementary experience in accompanying growth and internationalization as well as executing buy-and-build strategies.

Following the transaction, Peter Regneri, long-time shareholder and managing director, emphasizes the importance of handing over DETAX to an experienced consortium of mid-market investors with an international positioning, that is equipped to secure and continue the successful development of the company.

Ursula Juretzki-Mangold and Ralf König, managing directors and future shareholders say: “We are proud of what the entire DETAX team has achieved in recent years. Together, we were able to accomplish dynamic growth, particularly through internationalization and new product innovations. With the Investor Consortium, we have found strong partners who support us with many years of experience and international know-how in the healthcare and medical technology markets. Together with our partners, we plan to invest in further product innovations and digitization as well as the further strengthening of our headquarters in Ettlingen.”

Tim Krume, Director at ECM, adds: “DETAX is an exceptionally attractive company. We are excited about the highly professional organization, led by a high-calibre, experienced and motivated management team, the strong market positioning as well as the excellent reputation of the group as a leading specialist for medical materials. We are extremely pleased to accompany DETAX’s successful growth trajectory in partnership with the management team.”

Herbert Seggewiß, Partner at PINOVA, further adds: “We are impressed by the development of the group and the entrepreneurial performance of the management team. We were particularly impressed by the high-quality and extensively MDR-certified product portfolio, the long-standing loyal partnerships with customers and suppliers, and the high level of innovation with a strong track record. We look forward to a successful collaboration with the management team.”

Robert Stein, Partner at Gilde Healthcare Private Equity, notes, “DETAX represents an excellent basis for further organic and inorganic growth. We look forward to adding value in the future with our broad international network as well as our deep industry expertise, especially with respect to buy-and-build.”

The Investor Consortium was advised on the transaction by KWM (legal and structuring), CODEX (market), PwC (finance & tax), Shearman & Sterling (financing documentation), GCA Altium (debt advisor) and Willis Towers Watson (insurance). Responsible for the transaction at ECM are Tim Krume, Axel Eichmeyer and Paul Hansen, at PINOVA Herbert Seggewiß, David Gilli and Aylin Akkay and at Gilde Healthcare Private Equity Robert Stein, Tom Klein Robbenhaar and Julian Primer. DETAX was jointly advised on the transaction by CMS, Crowe BPG and Kanzlei Wangler.

About ECM Equity Capital Management GmbH (‘ECM’)
ECM is a trusted growth partner for mid-sized enterprises and entrepreneurs in German-speaking Europe. Since 1995, ECM has raised the private equity funds GEP I-V with aggregate equity commitments of more than €1 billion and currently invests out of the fifth fund GEP V (€325 million). The funds invest primarily in leading mid-market companies with attractive growth potential in the context of ownership successions, partnership transactions and corporate spin-offs. Further information at: www.ecm-pe.de.

About PINOVA Capital GmbH („PINOVA”)
PINOVA Capital is an independent private equity firm investing in high-growth technology companies in German-speaking regions. PINOVA Capital focuses on “Mittelstand” companies with sales between €10 million and €75 million in the sectors industrial technology and information technology, characterized by significant growth potential, sustainable competitive advantages and a strong market position in their niche. Further information at: www.pinovacapital.com

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor with two fund strategies: Venture&Growth and Private Equity. The firm is headquartered in Utrecht (The Netherlands) with local offices in Frankfurt (Germany) and Cambridge (United States). Gilde Healthcare Private Equity participates in profitable lower mid-market healthcare companies based in North-Western Europe. The Private Equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market. Gilde Healthcare Venture & Growth invests in medtech, healthtech and therapeutics in Europe and North America. Further information at: www.gildehealthcare.com

About DETAX Group („DETAX“)
DETAX, headquartered in Ettlingen with around 110 employees, is a specialist for medical materials. For more than 65 years, DETAX has been developing silicones and light-curing resins for medical applications and 3D printing. The company is one of the world’s leading specialists in polymer materials with a focus on the dental and audio sectors. Further information at: www.detax.de

Categories: News

Tags:

KKR Announces New Partners and Managing Directors

KKR

NEW YORK–(BUSINESS WIRE)– KKR today announced a newly promoted group of 18 Partners and 42 Managing Directors, effective January 1, 2022.

“Congratulations to our senior leaders for not only reaching new career milestones at KKR but for all they have done to get to there. Their many contributions as well as their commitment to KKR’s culture and values have played a significant role not only in shaping our firm and inspiring our colleagues, but also in helping meet KKR’s mission of supporting our clients and the companies in which we invest. Today, we recognize and thank these individuals, and wish them continued success,” said Joe Bae and Scott Nuttall, Co-Chief Executive Officers of KKR.

The following individuals have been promoted to Partner at KKR:

  • Brandon Brahm – Private Equity Americas, New York
  • Doug Brody – Credit & Markets, New York
  • Cathy Cai – Capstone, Beijing
  • Brian Dillard – Credit & Markets, Hong Kong
  • Nancy Ford – Private Equity Americas, Menlo Park
  • Felix Gernburd – Private Equity Americas, Menlo Park
  • Jake Heller – Next Generation Technology, New York
  • Craig Lee – Insurance & Strategic Finance, New York
  • Ted Oberwager – Private Equity Americas, New York
  • Sandra Ozola – Human Capital, New York
  • James Rudy – Global Macro & Asset Allocation, Balance Sheet and Risk, New York
  • Hardik Shah – Infrastructure, Mumbai
  • Steve Shanley – Next Generation Technology, London
  • Alberto Signori – Infrastructure, London
  • Chris Sun – Private Equity Asia Pacific, Beijing
  • Waldemar Szlezak – Infrastructure, New York
  • Joel Traut – Real Estate Credit, New York
  • Nick Zeitlin – Capstone, Menlo Park

The following individuals have been promoted to Managing Director at KKR:

  • Racim Allouani – Global Macro & Asset Allocation, Balance Sheet and Risk, New York
  • Ian Anderson – Credit & Markets, London
  • Jan Baumgart – Real Estate Equity, Frankfurt
  • Yacine Boumahrat – Client and Partner Group, Paris
  • Bradley Brown – Private Equity Americas, Menlo Park
  • Steve Codispoti – Finance, Tax and Accounting, New York
  • Benjamin Conner – Energy Real Assets, Houston
  • Aidan Corcoran – Global Macro & Asset Allocation, Balance Sheet and Risk, Dublin
  • Hunter Craig – Private Equity Americas, Menlo Park
  • Kate de Mul – Global Markets Operations, New York
  • Brandon Donnenfeld – Client and Partner Group, New York
  • Mark Ennis – Credit & Markets, London
  • Paul Fine – Real Estate Credit, New York
  • Federica Gironi – Credit & Markets, London
  • James Gordon – Infrastructure, London
  • Lauren Hahn – Credit & Markets, New York
  • Beth Hammond – Client and Partner Group, New York
  • Greg Hickey – Global Markets Operations, Dublin
  • Paul Horwood – Finance, Tax and Accounting, London
  • Hadi Husain – Global Macro & Asset Allocation, Balance Sheet and Risk, New York
  • David Katz – Public Policy and Affairs, Singapore
  • Jason Kelley – Real Estate Credit, New York
  • Brandi Kendall – Energy Real Assets, Houston
  • Keith Kim – Infrastructure, Seoul
  • David Kirby – Credit & Markets, New York
  • Scott Lazarz – Technology, Engineering and Data, New York
  • Joshua Lederman – Credit & Markets, New York
  • Jenn Lee – Credit & Markets, San Francisco
  • Rony Ma – Credit & Markets, New York
  • James Marsh – Client and Partner Group, London
  • Kyle Matter – Global Impact, New York
  • Hilary McNamara – Human Capital, New York
  • Johnny Mullins – Credit & Markets, Dublin
  • Ryan Murphy – Credit & Markets, New York
  • Thomas Murphy – Finance, Tax and Accounting, San Francisco
  • Matthew Ross – Credit & Markets, New York
  • Oleg Shamovsky – Infrastructure, London
  • Mike Shea – Finance, Tax and Accounting, New York
  • Peter Sundheim – Real Estate Equity, New York
  • Ananya Tripathi – Capstone, Mumbai
  • Paul Wasserman – Real Estate Equity, Houston
  • Michael Whyte – Real Estate Equity, New York

About KKR

KKR is a leading global investment firm that offers alternative asset management and capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of The Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com and on Twitter @KKR_Co.

Media
Cara Major
212-750-8300
media@kkr.com

Source: KKR & Co. Inc.

Categories: People

Audax Private Equity Completes the Sale of Katena Products to Corza Medical, a GTCR Portfolio Company

Audax Group

Audax Private Equity (“Audax”) today announced that it has successfully completed the sale of Katena Products (“Katena” or the “Company”) to Corza Medical (“Corza”), a GTCR portfolio company.

Katena is a leading global provider of precision ophthalmic instruments and therapeutics to physician offices, hospitals, surgical centers, distributors, medical device OEMs, and clinics. Founded in 1975 and headquartered in Parsippany, New Jersey, Katena’s product offering includes precision surgical instruments, single-use devices, and specialty biologics that are sold in over 110 countries through a network of direct salespeople and distributors. Katena has more than 200 employees across Europe and North America and serves over 5,000 customers around the world.

Since being acquired by Audax in 2015, Katena has undergone a period of transformation, growth, and success:

Invested in systems and IT infrastructure, including ERP and CRM systems upgrades, to support product quality, realize operational efficiencies, and drive sales
Expanded and improved manufacturing capabilities and infrastructure, including integration of supply chain with a continued focus on insourcing initiatives
Completed eight acquisitions in order to expand the Company’s product portfolio, geographic presence, and manufacturing capabilities
David Wong, Managing Director at Audax, said, “We’ve enjoyed a terrific partnership with the Katena team and are very proud of the growth the Company has achieved. Over the course of our investment, Katena has expanded both its product portfolio and customer base via organic growth and strategic acquisitions. We wish the team continued success as a part of Corza Medical with GTCR’s support.”

Steve Blazejewski, Chief Executive Officer of Katena, commented, “Audax has been an instrumental partner in helping Katena evolve into a leading ophthalmic products platform. With the support of Audax’ deep investment expertise, global resources, and operational experience, we have been able to accelerate our growth plans while enhancing our ability to meet the needs of our global customer base. We thank Audax for their partnership and look forward to embarking on our next phase of growth as a part of Corza Medical.”

Robert W. Baird & Co served as financial advisor and Kirkland & Ellis served as legal advisor to Katena.

Categories: News

OPAL Fuels, a Leading Vertically Integrated Producer and Distributor of Renewable Natural Gas, to List on Nasdaq through Combination with ArcLight Clean Transition Corp. II

Arclight

OPAL Fuels LLC has entered into a business combination agreement with ArcLight Clean
Transition Corp. II (Nasdaq: ACTD) (“ArcLight”) with an enterprise value of $1.75 billion;
upon closing, the combined company will be listed on the Nasdaq Exchange under the ticker
symbol “OPL”.
 OPAL Fuels is a leading vertically integrated producer and distributor of renewable natural
gas (“RNG”) with a diversified revenue and customer base in 42 states.
 Transaction includes a $125 million fully committed common stock PIPE at $10.00 per share
anchored by NextEra Energy, Inc. (NYSE: NEE) (“NextEra Energy”), Electron Capital
Partners, Gunvor Group, Wellington Management and Adage Capital Management, with
participation by ArcLight affiliates.
 Additionally, affiliates of NextEra Energy have made a commitment for up to a $100 million
preferred equity investment in OPAL Fuels and have entered into a purchase and sale
agreement for the majority of OPAL Fuels environmental attributes.
 Assuming no redemptions, the transactions are expected to provide gross proceeds of
approximately $536 million to fund the construction of OPAL Fuels’ robust RNG development
pipeline.

WHITE PLAINS, N.Y. – (December 2, 2021) – OPAL Fuels LLC (“OPAL Fuels” or the
“Company”), a leading vertically integrated producer and distributor of renewable natural gas
(RNG), and ArcLight Clean Transition Corp. II (Nasdaq: ACTD) (“ArcLight”), a publicly-traded
special purpose acquisition company, announced today a definitive agreement for a business
combination that will result in OPAL Fuels becoming a publicly listed company. Upon closing of
the transaction, the combined company will be named OPAL Fuels Inc. and remain listed on the
Nasdaq Stock Exchange under the new ticker symbol “OPL.” The combined company will
continue to be led by OPAL Fuels co-CEOs Adam Comora and Jonathan Maurer.
RNG is a proven low-cost, low-carbon fuel that when used in transportation in place of diesel fuel
can cost 40 to 70 percent less per gallon, providing significant annual operating cost savings while
dramatically reducing the carbon footprint of heavy duty fleets.

OPAL Fuels, a FORTISTAR portfolio company, is a vertically integrated, waste-to-fuel RNG
production and distribution company with a Capture and Conversion upstream business and
Dispensing and Monetization downstream business serving the domestic heavy duty transportation
sector. Underpinned by gas rights agreements that are typically at least twenty years in length,
Capture and Conversion projects produce RNG by capturing methane emissions from landfill sites
and dairy farms. The captured methane emissions are purified and treated, turning once harmful
emissions into a source of clean, renewable energy, reducing the harmful long-term effects of
methane and carbon emissions. This flips a substantial cost – managing dairy waste and landfill
gas – into significant revenue streams for dairy farms and landfills. OPAL Fuels’ Dispensing and
Monetization operations help deliver this clean, reliable and renewable fuel to heavy duty trucking
fleets through OPAL Fuels’ national network of fueling stations, which spans 42 states and is
typically backed by fueling agreements averaging ten years in duration.
OPAL Fuels is also positioned for a future that includes the commercialization of emerging
technologies, including renewable hydrogen, through existing partnerships with key industry
participants. The company is well placed to be an enabler of renewable hydrogen that uses RNG
in its production and to develop, construct, and operate heavy duty hydrogen fueling station
networks.

OPAL Fuels has a proven business model, tracing its roots back to 1998, and is expected to
generate nearly $170 million in revenues in 2021. The company’s vertically integrated model
benefits its margin profile and positions the company well to capture share in a fragmented industry
that is characterized by smaller, non-vertically integrated upstream and downstream participants.
Today, OPAL Fuels operates 21 biomethane projects, of which three are in RNG service and the
balance are in renewable power service. Increasing secular tailwinds, which include public policy
initiatives and corporate sustainability objectives, are supporting the growth of RNG as a way to
cost effectively halt climate change and decarbonize transportation, providing strong visibility into
significant volume and EBITDA growth for OPAL Fuels over the next several years. The
company’s project pipeline totals 23, seven of which are in construction and the balance of which
are in advanced development execution.

Management Commentary
Adam Comora, co-CEO of OPAL Fuels, stated, “This transaction with ArcLight reflects a
transformative step in our company’s development and strategy. RNG powered heavy duty fleets
realize substantial savings today versus diesel and the successful execution of our robust growth
plans will expand the role of ultra low-carbon RNG across the transportation sector. By capturing
harmful fugitive methane emissions and replacing traditional fossil fuel usage, we will advance
the sustainability and decarbonization goals of public policy makers, our customers and our

partners across the nation. RNG is a right now solution to the right now problem of climate change.
RNG is one of the most attractive sources of renewable energy – its production uses existing
technologies proven at scale, it can be transported on existing pipeline infrastructure, and it can be
stored effectively until its use, all of which lead to a cost competitive and reliable fuel source. We
are thrilled to partner with ArcLight, as we believe their experience as a leading energy
infrastructure asset manager is a strong vote of confidence in the bright future of our company. We
look forward to leveraging their expertise as we execute on our business model.”
Jonathan Maurer, co-CEO of OPAL Fuels, commented, “It is an incredibly exciting time at OPAL
Fuels. The market for RNG as a transportation fuel is at an inflection point, and we are excited to
leverage our expertise in renewable power to be a leader in RNG projects as we convert renewable
power projects to renewable transportation fuel facilities. Our seasoned team, which includes
several leaders that have more than 25 years of experience in the industry, is excited to execute on
our robust project pipeline and deliver value to all of our stakeholders.”
Jake Erhard, President and CEO of ArcLight Clean Transition Corp. II said, “OPAL Fuels is a
leading platform for the production and distribution of ultra low-carbon RNG to the transportation
sector, the highest value end-market for RNG. The company’s vertically integrated model
differentiates it from other players in the industry, which together with the platform’s more than
two decades of experience gives us tremendous confidence in the company’s ability to execute its
growth plans. Importantly, OPAL Fuels’ business contributes meaningfully to sustainable
development in the transportation, waste management and agricultural industries by enabling the
adoption of leading-edge methane capture technologies and processes that drastically reduce
greenhouse gas emissions.”
John Ketchum, President and CEO of NextEra Energy Resources, said, “We’re excited about this
opportunity with OPAL Fuels to leverage renewable natural gas to produce and distribute ultra
low-carbon fuels that are helping drive decarbonization of the transportation sector. This
investment is consistent with our strategy to help lead the decarbonization of the transportation,
electricity and industrial sectors in the U.S.”

Transaction Overview
The business combination values OPAL Fuels at an implied $1.75 billion pro forma enterprise
value at a price of $10.00 per ArcLight share. The transaction and related financings are expected
to provide gross proceeds of approximately $536 million to OPAL Fuels, comprised of:
 ArcLight’s $311 million of cash held in trust, assuming no redemptions,
 A $125 million fully committed PIPE, anchored by NextEra Energy, an affiliate of
ArcLight, Electron Capital Partners, Gunvor Group, Wellington Management and Adage
Capital Management, and;

 Up to a $100 million preferred equity investment from affiliates of NextEra Energy.
The boards of directors of both ArcLight Clean Transition Corp. II and OPAL Fuels have approved
the proposed transaction, which is expected to be completed in the second quarter of 2022, subject
to, among other things, approval by ArcLight’s stockholders and satisfaction or waiver of other
conditions stated in the definitive documentation.
Additional information about the proposed transaction, including a copy of the merger agreement
and investor presentation, will be provided in a Current Report on Form 8-K to be filed by ArcLight
with the Securities and Exchange Commission and available at https://www.sec.gov/.

Advisors
BofA Securities, Inc. (“BofA Securities”) is serving as lead financial advisor and Credit Suisse
Securities (USA) LLC (“Credit Suisse”) is serving as financial advisor while Sheppard Mullin
Richter & Hampton LLP is serving as legal advisor to OPAL Fuels. Citigroup Global Markets Inc.
(“Citi”) is serving as lead financial advisor and Barclays Capital Inc. (“Barclays”) is serving as
financial advisor while Kirkland & Ellis LLP is serving as legal advisor to ArcLight. Citi, BofA
Securities, Barclays and Credit Suisse are serving as joint placement agents on the PIPE offering,
while Winston & Strawn LLP is counsel to the Placement Agents. J.P. Morgan Securities LLC
served as sole financial advisor and Hogan Lovells US LLP acted as counsel to NextEra Energy
on the transaction.

Investor Conference Call Information
OPAL Fuels and ArcLight will host a joint investor conference call at 8:30 AM ET today,
December 2, 2021, to discuss the proposed transaction. To listen to the prepared remarks via
telephone dial 1-877-407-3982 (U.S.) or 1-201-493-6780 (International) and an operator will assist
you. A telephone replay will be available at 1-844-512-2921(U.S.) or 1-412-317-6671
(International), PIN: 13725376 through December 16, 2021 at 11:59 PM ET. A transcript of this
conference call can also be found on OPAL Fuels’ Investor page and will be filed by ArcLight
with the SEC.

About OPAL Fuels LLC
OPAL Fuels LLC, a FORTISTAR portfolio company, is a leading vertically integrated renewable
fuels platform involved in the production and distribution of renewable natural gas (RNG) for the
heavy-duty truck market. RNG is a proven low carbon fuel that is rapidly decarbonizing the
transportation industry now while also significantly reducing costs for fleet owners. OPAL Fuels
captures harmful methane emissions at the source and recycles the trapped energy into a
commercially viable, low-cost alternative to diesel fuel. OPAL Fuels also develops and constructs
RNG fueling stations. As a producer and distributor of carbon-reducing fuel for heavy-duty truck
fleets for over 15 years, the company delivers best-in-class, complete renewable solutions to
customers and production partners. To learn more about OPAL Fuels and how it is leading the
effort to capture North America’s harmful methane emissions and decarbonize the transportation
industry, please visit www.opalfuels.com and follow the company on LinkedIn and Twitter at
@OPALFuels.

About ArcLight Clean Transition Corp. II
ArcLight, ArcLight Clean Transition Corp. II, led by Chairman Daniel Revers and President and
Chief Executive Officer Jake Erhard, is a special purpose acquisition company formed for the
purpose of effecting a capital stock exchange, asset acquisition, share purchase, reorganization, or
similar business combination with one or more businesses focused on opportunities created by the
accelerating transition toward sustainable use of energy and natural resources.

About FORTISTAR
Founded in 1993, FORTISTAR is a privately-owned investment firm that provides capital to build,
grow and manage companies that address complex sustainability challenges. FORTISTAR utilizes
its capital, flexibility and operating expertise to grow high-performing assets, first in independent
power projects and now into other areas that support decarbonization. For more information about
FORTISTAR or its portfolio companies, please visit: www.fortistar.com and follow the company on
LinkedIn.

Forward-Looking Statements
Certain statements in this communication may be considered forward-looking statements.
Forward-looking statements are statements that are not historical facts and generally relate to
future events or ArcLight’s or the Company’s future financial or other performance metrics. In
some cases, you can identify forward-looking statements by terminology such as “believe,” “may,”
“will,” “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “would,” “project,”
“target,” “plan,” “expect,” or the negatives of these terms or variations of them or similar
terminology. Such forward-looking statements, including the identification of a target business
and a potential business combination or other such transaction are subject to risks and
uncertainties, which could cause actual results to differ materially from those expressed or implied
by such forward looking statements. New risks and uncertainties may emerge from time to time,
and it is not possible to predict all risks and uncertainties. These forward-looking statements are
based upon estimates and assumptions that, while considered reasonable by ArcLight and its
management, and the Company and its management, as the case may be, are inherently uncertain
and subject to material change. Factors that may cause actual results to differ materially from
current expectations include, but are not limited to, various factors beyond management’s control,
including general economic conditions and other risks, uncertainties and factors set forth in the
section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in
ArcLight’s final prospectus relating to its initial public offering, dated September 22, 2020, and
other filings with the Securities and Exchange Commission (SEC), including the registration
statement on Form S-4 to be filed by ArcLight in connection with the transaction, as well as (1)
the inability to complete the proposed transaction; (2) factors associated with companies, such as
the Company, that are engaged in the production and integration of renewable natural gas (RNG),
-6-
including anticipated trends, growth rates, and challenges in those businesses and in the markets
in which they operate; (3) macroeconomic conditions related to the global COVID-19 pandemic;
(4) the effects of increased competition; (5) contractual arrangements with, and the cooperation of,
landfill and livestock waste site owners and operators, on which the Company operates its landfill
gas and livestock waste projects that generate electricity and RNG prices for environmental
attributes, low carbon fuel standard credits and other incentives; (6) the ability to identify, acquire,
develop and operate renewable projects and RNG fueling stations; (7) the failure to realize the
anticipated benefits of the proposed transaction, which may be affected by, among other things,
competition, the ability of the combined company to grow and manage growth profitably, maintain
relationships with customers and suppliers and retain key employees; (8) delays in obtaining,
adverse conditions contained in, or the inability to obtain necessary regulatory approvals or
complete regulatory reviews required to complete the proposed transaction; (9) the outcome of any
legal proceedings that may be instituted in connection with the proposed transaction; (10) the
amount of redemption requests made by ArcLight’s public shareholders; and (11)the ability of the
combined company that results from the proposed transaction to issue equity or equity-linked
securities or obtain debt financing in connection with the transaction or in the future. Nothing in
this communication should be regarded as a representation by any person that the forward-looking
statements set forth herein will be achieved or that any of the contemplated results of such forwardlooking statements will be achieved. You should not place undue reliance on forward-looking
statements in this communication, which speak only as of the date they are made and are qualified
in their entirety by reference to the cautionary statements herein. Both ArcLight and the Company
expressly disclaim any obligations or undertaking to release publicly any updates or revisions to
any forward-looking statements contained herein to reflect any change in ArcLight’s or the
Company’s expectations with respect thereto or any change in events, conditions or circumstances
on which any statement is based.
Important Information and Where to Find It
A full description of the terms of the transaction will be provided in a registration statement on
Form S-4 to be filed with the SEC by ArcLight that will include a prospectus with respect to the
combined company’s securities to be issued in connection with the business combination and a
proxy statement with respect to the shareholders meeting of ArcLight to vote on the business
combination. ArcLight urges its investors, shareholders and other interested persons to read,
when available, the preliminary proxy statement/prospectus as well as other documents filed
with the SEC because these documents will contain important information about ArcLight,
the Company and the transaction. After the registration statement is declared effective, the
definitive proxy statement/prospectus to be included in the registration statement will be mailed to
shareholders of ArcLight as of a record date to be established for voting on the proposed business
combination. Once available, shareholders will also be able to obtain a copy of the S-4, including
the proxy statement/prospectus, and other documents filed with the SEC without charge, by
directing a request to: ArcLight Clean Transition Corp. II, 200 Clarendon Street, 55th Floor,
Boston, Massachusetts 02116. The preliminary and definitive proxy statement/prospectus to be
included in the registration statement, once available, can also be obtained, without charge, at the
SEC’s website (www.sec.gov).
Participants in the Solicitation

ArcLight and the Company and their respective directors and officers may be deemed to be
participants in the solicitation of proxies from ArcLight’s shareholders in connection with the
proposed transaction. Information about ArcLight’s directors and executive officers and their
ownership of ArcLight’s securities is set forth in ArcLight’s filings with the SEC. To the extent
that holdings of ArcLight’s securities have changed since the amounts printed in ArcLight’s
Registration Statement on Form S-1, such changes have been or will be reflected on Statements of
Change in Ownership on Form 4 filed with the SEC. Additional information regarding the interests
of those persons and other persons who may be deemed participants in the proposed transaction
may be obtained by reading the proxy statement/consent solicitation statement/prospectus
regarding the proposed transaction when it becomes available. You may obtain free copies of these
documents as described in the preceding paragraph.
Non-Solicitation
This communication is not a proxy statement or solicitation of a proxy, consent or authorization
with respect to any securities or in respect of the potential transaction and shall not constitute an
offer to sell or a solicitation of an offer to buy the securities of ArcLight, the Company or the
combined company, nor shall there be any sale of any such securities in any state or jurisdiction
in which such offer, solicitation, or sale would be unlawful prior to registration or qualification
under the securities laws of such state or jurisdiction. No offer of securities shall be made except
by means of a prospectus meeting the requirements of the Securities Act.

Contact information
OPAL Fuels
Investors
ICR, Inc.
OPALFuelsIR@icrinc.com
Media
Jason Stewart
Senior Director Public Relations and Marketing
914-421-5336
jstewart@opalfuels.com
ICR, Inc.
OPALFuelsPR@icrinc.com
ArcLight Clean Transition Corp. II
Marco Gatti
Chief Financial Officer
617-531-6300
investor.relations@arclightclean.com

Categories: News

Tags:

3TS Capital Partners Exits SALESmanago to SilverTree Equity and Perwyn

3TS Capital Partners

Vienna, Warsaw, London, 2 December, 2021

3TS Capital Partners, a leading European growth capital investor, announced today that its portfolio company, SALESmanago has been successfully acquired by a private equity consortium composed of SilverTree Equity and Perwyn. SALESmanago is a leading SaaS no-code CDP & Marketing Automation platform. 3TS realized an exceptional return on the investment, as the Company grew revenues over 400% in the 5.5 years as part of the portfolio. This is 3TS’ third exit of 2021.

“We are delighted to have been part of SALESmanago’s journey and to be able to bring strategic guidance at critical inflection points, as the Company scaled revenues over 50% per year.”, said Zbigniew Lapinski, Partner at 3TS Capital Partners. “Greg and the entire team have done an incredible job growing SALEmanago from a local leader to a breakthrough technology and a global challenger in the marketing automation platform segment.”

“3TS worked closely with us and supported SALESmanago with operational insights through tremendous growth, as well as during the challenging moments of great change as our Company evolved.” added Greg Blazewicz, SALESmanago’s Founder and CEO.

SilverTree Equity and Perwyn acquired SALESmanago in a nine-digit transaction, which included a growth investment that the Company will use for further expansion. SilverTree Equity is a leading UK-based private equity firm with deep expertise in technology and software businesses. Perwyn is a UK-based family-backed private equity investor.

About SALESmanago

Headquartered in Krakow and founded in 2012, SALESmanago is a leading SaaS marketing automation and Customer Data Platform company. Its solution harnesses the full power of first- and zero-party data, combining advanced analytics and AI automation to deliver highly configurable personalized experiences, across a comprehensive range of natively built and integrated marketing execution channels. SALESmanago’s customers are a mix of large blue chip and mid-size organizations located across Europe, the Americas and Asia and spanning all industry verticals. Customers include Starbucks, Burger King, Pizza Hut, BMW, Toyota, Harley Davidson, Victoria’s Secret, Crocs and T-Mobile.

For more information, please visit www.salesmanago.com

About 3TS Capital Partners

3TS Capital Partners is a technology focused growth capital firm investing across Central Europe. 3TS provides expansion capital for businesses in growth sectors including Technology & Internet, Media & Communications and Technology-Enabled Services. The combination of strong financial backing, strategic value-add and extensive networks form the foundation of the 3TS company-building strategy. Investors in the current and past 3TS funds totaling over €400 million include EIF, Erste Group, Tesi, Cisco, OTP, EBRD, AWS, Sitra, KfW, and 3i among others.

For more information, please visit www.3tscapital.com

Categories: News

Tags: